Actinium Pharmaceuticals, Inc. (ATNM) Research

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.

Market snapshot

Symbol
ATNM
Price
$1.03
Day change
+0.98%
Market cap
$32.3M
P/E ratio
-1.37x
52-week range
0.952-1.89
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$11.07

Peer companies

  • Annovis Bio, Inc. (ANVS)
  • FibroGen, Inc. (FGEN)
  • Kezar Life Sciences, Inc. (KZR)
  • LAVA Therapeutics N.V. (LVTX)
  • OnKure Therapeutics, Inc. (OKUR)
  • PDS Biotechnology Corporation (PDSB)
  • Reviva Pharmaceuticals Holdings, Inc. (RVPH)
  • Tempest Therapeutics, Inc. (TPST)

Recent insider activity

  • SETH SANDESH — F-InKind (120900 shares) on 2025-08-18
  • Steinhart Richard I — D-Return (72156 shares) on 2025-03-31
  • Steinhart Richard I — D-Return (8333 shares) on 2025-03-31
  • Steinhart Richard I — D-Return (2500 shares) on 2025-03-31
  • Steinhart Richard I — D-Return (2500 shares) on 2025-03-31

Open Actinium Pharmaceuticals, Inc. (ATNM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.